1. The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
- Author
-
Masako Kohyama, Yoshiaki Yamagishi, Kanako Akamatsu, Daron M. Standley, Noriko Arase, Hisashi Arase, Jun-ichi Kishikawa, Songling Li, Yafei Liu, Mika Hirose, Chikako Ono, Hui Jin, Atsushi Kumanogoh, Kazuki Kishida, Akemi Arakawa, Sumiko Matsuoka, Asa Tada, Takayuki Kato, Hironori Nakagami, Yoshiharu Matsuura, Wataru Nakai, Masato Okada, Atsushi Nakagawa, and Manabu Fujimoto
- Subjects
Delta ,Infectivity ,Messenger RNA ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,biology.protein ,Wild type ,Biology ,Antibody ,Virology - Abstract
mRNA-based vaccines provide effective protection against most common SARS-CoV-2 variants. However, identifying likely breakthrough variants is critical for future vaccine development. Here, we found that the Delta variant completely escaped from anti-N-terminal domain (NTD) neutralizing antibodies, while increasing responsiveness to anti-NTD infectivity-enhancing antibodies. Although Pfizer-BioNTech BNT162b2-immune sera neutralized the Delta variant, when four common mutations were introduced into the receptor binding domain (RBD) of the Delta variant (Delta 4+), some BNT162b2-immune sera lost neutralizing activity and enhanced the infectivity. Unique mutations in the Delta NTD were involved in the enhanced infectivity by the BNT162b2-immune sera. Sera of mice immunized by Delta spike, but not wild-type spike, consistently neutralized the Delta 4+ variant without enhancing infectivity. Given the fact that a Delta variant with three similar RBD mutations has already emerged according to the GISAID database, it is necessary to develop vaccines that protect against such complete breakthrough variants.
- Published
- 2021
- Full Text
- View/download PDF